Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 16/20 | 0.32 |
| ▸ | ITGAV | P06756 | 15/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 14/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12334338 | 1.00 | HRH3 (0.38) | HRH3GHSRITGB3ITGAVITGB5 | |
| SCHEMBL4410585 | 1.00 | HRH3 (0.38) | HRH3GHSRITGB3ITGAVITGB5 | |
| SCHEMBL27049693 | 0.80 | CRBN (0.42) | — | |
| SCHEMBL417814 | 0.80 | HRH3 (0.37) | HRH3GHSRITGB3ITGAVITGB5 | |
| SCHEMBL26229173 | 0.80 | HRH3 (0.37) | HRH3GHSRITGB3ITGAVITGB5 | |
| SCHEMBL31420767 | 0.80 | HRH3 (0.37) | HRH3ITGB3ITGAVITGB5ITGA2B | |
| SCHEMBL6948618 | 0.80 | HRH3 (0.37) | HRH3GHSRITGB3ITGAVITGB5 | |
| SCHEMBL17966443 | 0.80 | ITGB3 (0.39) | HRH3ITGB3ITGAVITGB5ITGA2B | |
| SCHEMBL10417796 | 0.80 | ITGB3 (0.39) | HRH3ITGB3ITGAVITGB5ITGA2B | |
| SCHEMBL10417797 | 0.80 | ITGB3 (0.39) | HRH3ITGB3ITGAVITGB5ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969002-B2 | Savoury and mouthfulness taste enhancers | LUCTA, S.A. (ES) | 2024-04-30 | — | — | US | disclosed |
| EP-3864012-B1 | SAVOURY AND MOUTHFULNESS TASTE ENHANCERS | LUCTA S A (ES) | 2023-09-13 | — | — | EP | disclosed |
| US-20210337850-A1 | SAVOURY AND MOUTHFULNESS TASTE ENHANCERS | LUCTA, S.A. (ES) | 2021-11-04 | — | — | US | disclosed |
| EP-3864012-A1 | SAVOURY AND MOUTHFULNESS TASTE ENHANCERS | Lucta, S.A. (ES) | 2021-08-18 | — | — | EP | disclosed |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8435997-B2 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435997-B2 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | UWM RESEARCH FOUNDATION, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8173809-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173809-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | MARQUETTE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | MARQUETTE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| US-7829709-B1 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829709-B1 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY | 2009-11-12 | — | — | US | disclosed |
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY | 2009-11-12 | — | — | US | disclosed |
| WO-2009100431-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | HRH3 1934/4885GHSR 3056/4885ITGB3 4338/4885 |
| US-20210337850-A1 | SAVOURY AND MOUTHFULNESS TASTE ENHANCERS | KCNJ6, TAS1R1, TAS2R5 | HRH3 1842/4885GHSR 1507/4885ITGB3 4336/4885 |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | HRH3 1934/4885GHSR 3056/4885ITGB3 4338/4885 |
| US-11969002-B2 | Savoury and mouthfulness taste enhancers | TAS1R1, KCNJ6, KCNJ5 | HRH3 1800/4885GHSR 1455/4885ITGB3 4361/4885 |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | SLC7A11, CBS, CTH | HRH3 2717/4885GHSR 2179/4885ITGB3 4424/4885 |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | CTH, CBS, SLC6A3 | HRH3 3124/4885GHSR 3265/4885ITGB3 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.